Press releases
- Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum
- Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases
- Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split
- Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
- Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
- Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
- Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
More ▼
Key statistics
As of last trade, Atara Biotherapeutics Inc (AT20:DEU) traded at 7.00, 55.56% above the 52 week low of 4.50 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.00 |
---|---|
High | 7.00 |
Low | 7.00 |
Bid | 7.47 |
Offer | 7.97 |
Previous close | 7.03 |
Average volume | 8.50 |
---|---|
Shares outstanding | 4.90m |
Free float | 4.46m |
P/E (TTM) | -- |
Market cap | 37.81m USD |
EPS (TTM) | -52.93 USD |
Data delayed at least 15 minutes, as of Jun 28 2024.
More ▼